# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001193125-26-016553
**Filing Date:** 2026-1
**Character Count:** 26320
**Document Hash:** 4778d4be092fde0eae440125f4c7a6da
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-016553.hdr.sgml**: 20260120

**ACCESSION NUMBER**: 0001193125-26-016553

**CONFORMED SUBMISSION TYPE**: SC TO-C

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260120

**DATE AS OF CHANGE**: 20260120

**GROUP MEMBERS**: GLAXOSMITHKLINE LLC

**GROUP MEMBERS**: REDROSE ACQUISITION CO.

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RAPT Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001673772
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473313701
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91191
- **FILM NUMBER:** 26542824

**BUSINESS ADDRESS:**
- **STREET 1:** 561 ECCLES AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 489-9000

**MAIL ADDRESS:**
- **STREET 1:** 561 ECCLES AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLX Bio, Inc.
- **DATE OF NAME CHANGE:** 20160504
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** SC TO-C

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE TO** 

**Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)** 

**of the Securities Exchange Act of 1934** 

## RAPT THERAPEUTICS, INC.
**(Name of Subject Company)** 

**REDROSE ACQUISITION CO.,** 

**GLAXOSMITHKLINE LLC** 

**and** 

**GSK PLC** 

**(Name of Filing Persons (Offerors))** 

**Common Stock, par value $0.0001 per share** 

**(Title of Class of Securities)** 

**75382E208** 

**(CUSIP Number of Class of Securities)** 

**David Rea** 

**GlaxoSmithKline LLC** 

**1250 South Collegeville Road** 

**Collegeville, PA 19426** 

**+1 215-219-7521** 

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)** 

**Copy to:** 

**George Karafotias** 

**Beth Troy** 

**Allen Overy Shearman Sterling US LLP** 

**599 Lexington Avenue** 

**New York, NY 10022** 

**Telephone: +1 (212) 848-4000** 

**Calculation of Filing Fee** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**Transaction Valuation** | **Amount of Filing Fee** |
| &nbsp;&nbsp;&nbsp;N/A | N/A |

---

☐ Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and date of its filing.

---

| | |
|:---|:---|
| Amount Previously Paid: N/A | Filing Party: N/A |
| Form of Registration No.: N/A | Date Filed: N/A |

---

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ third-party tender offer subject to Rule 14d-1.

☐ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

------

**SCHEDULE TO** 

The pre-commencement communications filed under cover of this Tender Offer Statement on Schedule TO are being filed by GSK plc, a public limited company organized under the laws of England and Wales ("<u>GSK plc</u>"), pursuant to General Instruction D to Schedule TO relate to a planned cash tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share (the "<u>Shares</u>"), of RAPT Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), pursuant to an Agreement and Plan of Merger, dated as of January 19, 2026, by and among GlaxoSmithKline LLC, a Delaware limited liability company and a wholly-owned subsidiary of GSK plc ("<u>Parent</u>"), Redrose Acquisition Co., a Delaware corporation and a wholly-owned subsidiary of Parent ("<u>Purchaser</u>"), the Company, and solely for purposes of Section 8.11 therein, GSK plc, a public limited company organized under the laws of England and Wales.

**Additional Information** 

The tender offer for the Shares referenced in this announcement has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell Shares or any other securities, nor is it a substitute for the tender offer materials that GSK plc, Parent and Purchaser will file or cause to be filed with the Securities and Exchange Commission (the "<u>SEC</u>") upon the commencement of the tender offer. At the time the tender offer is commenced, GSK plc, Parent and Purchaser will file or cause to be filed with the SEC a tender offer statement on Schedule TO (the "<u>Tender Offer Statement</u>"), and the Company will file with the SEC a solicitation/recommendation statement on Schedule 14D-9 (the "<u>Solicitation/Recommendation Statement</u>"), in each case, with respect to the tender offer. **THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER.** The tender offer for Shares will be made only pursuant to the Offer to Purchase, the Letter of Transmittal and related documents filed as a part of the Tender Offer Statement. The Tender Offer Statement (including the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents), as well as the Solicitation/Recommendation Statement, will be made available to all holders of Shares at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the SEC's website at www.sec.gov. Copies of the documents filed by GSK plc, Parent and Purchaser with the SEC will also be available free of charge on GSK plc's website at https://www.gsk.com/en-gb/investors or by contacting GSK plc's investor relations department at gsk.investor.relations@gsk.com. Copies of the documents filed by the Company with the SEC will also be available free of charge on the Company's investor relations website at https://investors.rapt.com/investor-relations. In addition, stockholders of the Company may obtain free copies of the tender offer materials by contacting the information agent for the tender offer that will be named in the Tender Offer Statement.

**Forward-looking Statements** 

GSK plc cautions investors that any forward-looking statements or projections made by GSK plc, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK plc's Annual Report on Form 20-F for the year ended December 31,

------

2024. The pre-commencement communications filed under cover of this Tender Offer Statement on Schedule TO include forward-looking statements related to the Company, ozureprubart and the acquisition of the Company by GSK plc, Parent and Purchaser that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the Company and members of its senior management team and can typically be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the business combination, similar transactions, prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for the Company's business; the commercial success of the Company's products; the anticipated timing of clinical data and regulatory filings or approvals relating to products; the possibility of favourable or unfavourable results from clinical trials; the anticipated benefits of the acquisition; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the parties' ability to complete the transaction; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and completion of the merger; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that the Company stockholders may not tender into the offer a majority of the Shares outstanding at the time of the expiration of the offer or that required regulatory approvals may not be obtained or are obtained subject to conditions that are not anticipated; the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger; the failure to realize anticipated benefits of the proposed acquisition when expected or at all; potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the announcement, pendency or consummation of the acquisition on the ability of the Company to retain and hire key personnel or maintain key vendor, supplier or partner relationships; risks that the proposed acquisition disrupts the current plans and operations of the Company; transaction costs; risks associated with potential litigation or regulatory actions related to the transaction; and other risks and uncertainties described from time to time in documents filed with the SEC by the Company, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Solicitation/Recommendation Statement to be filed by the Company, or in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC by GSK plc, as well as the Tender Offer Statement to be filed by GSK plc, Parent and Purchaser. All forward-looking statements are based on information currently available to GSK plc and the Company neither GSK plc nor the Company assumes any obligation to update any forward-looking statements.

**\*\*\*** 

**Item 12.** **Exhibits.** <br>

---

| | |
|:---|:---|
| (a)(5)(a) | [GSK plc investor call slides, dated January 20, 2026](d874022dex99a5a.htm) |
| (a)(5)(b) | [Social media content by Kaivan Khavandi on https://www.linkedin.com/](d874022dex99a5b.htm) |
| (a)(5)(c) | [Social media content by Chris Sheldon on https://www.linkedin.com/](d874022dex99a5c.htm) |

---

## Ex-99.(A)(5)(A)

**Exhibit (a)(5)(a)**![LOGO](g874022g05a01.jpg)

Agreement to acquire RAPT Therapeutics <br>Lead asset: ozureprubart, a potential best-in-class, long-acting anti-IgE monoclonal antibody for food allergy

------

![LOGO](g874022g06a01.jpg)

Speakers <br>Luke Miels <br>Chief Executive Officer <br>Nina Mojas <br>President, Global Product <br>Strategy <br>Tony Wood <br>Chief Scientific Officer

------

![LOGO](g874022g07a01.jpg)

Disclosure statement <br>This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer or a recommendation to sell securities, nor is it a substitute for the tender offer materials that Redrose Acquisition Co., GlaxoSmithKline LLC and GSK plc will file with the Securities and Exchange Commission (the SEC). The tender offer for the outstanding shares of RAPT Therapeutics, Inc.'s (the Company) common stock described in this communication has not commenced. At the time the tender offer is commenced, Redrose Acquisition Co., GlaxoSmithKline LLC and GSK plc will file, or will cause to be filed, a Schedule TO Tender Offer Statement with the SEC and the Company will file a Schedule 14D-9 Solicitation/Recommendation Statement with the SEC, in each case with respect to the tender offer. The Schedule TO Tender Offer Statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the Schedule 14D-9 Solicitation/Recommendation Statement will contain important information that should be read carefully before any decision is made with respect to the tender offer. Those materials (once they become available) will be made available to the Company's stockholders at no expense to them by the information agent for the tender offer, which will be announced. In addition, those materials and all other documents filed, or caused to be filed, by Redrose Acquisition Co., GlaxoSmithKline LLC and GSK plc with the SEC will be available at no charge on the SEC's website at www.sec.gov

------

![LOGO](g874022g00q00.jpg)

4 Cautionary statement regarding forward-looking statements GSK plc cautions investors that any forward-looking statements or projections made by GSK plc, including those made in this communication, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2024. This communication includes forward-looking statements related to the Company, ozureprubart and the acquisition of the Company by GSK plc, Redrose Acquisition Co. and GlaxoSmithKline LLC that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the Company and members of its senior management team and can typically be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the business combination, similar transactions, prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for the Company's business; the commercial success of the Company's products; the anticipated timing of clinical data and regulatory filings or approvals relating to products; the possibility of favourable or unfavourable results from clinical trials; the anticipated benefits of the acquisition; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the parties' ability to complete the transaction; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and completion of the merger; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that the Company stockholders may not tender into the offer a majority of the shares outstanding at the time of the expiration of the offer or that required regulatory approvals may not be obtained or are obtained subject to conditions that are not anticipated; the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger; the failure to realize anticipated benefits of the proposed acquisition when expected or at all; potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the announcement, pendency or consummation of the acquisition on the ability of the Company to retain and hire key personnel or maintain key vendor, supplier or partner relationships; risks that the proposed acquisition disrupts the current plans and operations of the Company; transaction costs; risks associated with potential litigation or regulatory actions related to the transaction; and other risks and uncertainties described from time to time in documents filed with the SEC by the Company, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Solicitation/Recommendation Statement to be filed by the Company, or in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC by GSK plc, as well as the Tender Offer Statement to be filed by GSK plc, Redrose Acquisition Co. and GlaxoSmithKline LLC. All forward-looking statements are based on information currently available to GSK plc and the Company neither GSK plc nor the Company assumes any obligation to update any forward-looking statements.

------

![LOGO](g874022g08a01.jpg)

Agreement to acquire RAPT Therapeutics <br>Ozureprubart: potentially best-in-class, long-acting anti-IgE in phase IIb for food allergy (FA) <br>Strategic rationale <br>• Significant unmet need with >1.3m people impacted by severe FA in the US1 <br>• Ozureprubart is a potential best-in-class, longacting anti-IgE <br>• IgE is a clinically validated target in FA <br>• Strategically consistent with long-acting approach; complements extensive commercial footprint and prescriber base in allergy <br>Financial considerations <br>Deal consideration $2.2bn <br>GSK acquires global rights to ozureprubart (excl. mainland China, Macau, Taiwan and Hong Kong) <br>GSK responsible for success-based milestone and royalty payments to Shanghai Jeyou Pharmaceutical <br>Transaction expected to close Q1 2026 <br>1. MarketScan's overall prevalence, and Optum's age-stratified (<18; 18+) and overall prevalence. Severe FA defined as patients with ER/inpatient visit or under specialist care

------

![LOGO](g874022g09a01.jpg)

Food allergy has high unmet need with limited treatment options <br>Food allergy <br>>3m US patient visits each year to hospital/emergency care due to severe food allergies1 <br>~$33bn cost to US families in 2024 due to food allergies1 <br>65% of severe food allergy patients <18yr2 <br>~94% of severe food allergies are IgE driven2 <br>~25% of patients ineligible for existing anti-IgE therapy <br>US uptake of anti-IgE Ab therapy3 <br>1. FARE Food Allergy Facts and Statistics for the US (April 2024) 2. GSK Epi assessment based on MarketScan and Optum claims database <br>3. https://investors.rapt.com/static-files/5e90d821-377d-4b8a-ab4d-24768e266c56

------

![LOGO](g874022g10a01.jpg)

Anti-IgE use in proactive management requires a complex dosing schedule Proactive management is required for high-risk patients, or where standard management1 is insufficient Proactive management2,3 Approved anti-IgE dosing schedule4 Ozureprubart has potential to achieve: A differentiated, simplified and less frequent dosing regimen in patients eligible for currently-approved anti-IgE Broadening of patient population to include those ineligible for currently-approved anti-IgE 1. Standard management includes strict allergen avoidance and emergency preparedness 2. GSK EE (US) interviews, Nov-Dec 2025 3. Anagnostou A, Bird JA, Chinthrajah S, et al. The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2025 Jan;155(1):62-69.e1. doi: 10.1016/j.jaci.2024.09.031. Epub 2024 Nov 22. PMID: 39580718 4. https://www.gene.com/download/pdf/xolair_prescribing.pdf Single allergy (peanut) Allergen-specific Immunotherapy (AIT) High burden/ risk patient Single or multiple allergies Anti-IgE antibody At-risk of AIT reaction Anti-IgE antibody+ AIT combo therapy paeds (<18 yr old) only paeds + adults 7

------

![LOGO](g874022g11a01.jpg)

Anti-IgE: Clinically validated in allergic diseases Omalizumab approved in allergic asthma, CRSwNP, CSU and food allergy (US only) Anti-IgE MOA in food allergy Binds & sequesters circulating IgE Blocks FceRI cross-linking on mast cells Reduces CD23-mediated inflammation amplification loop Downregulates FceRI expression on effector cells Prevents both immediate & late-phase responses RAPT Therapeutics corporate presentation—Adapted from Dantzer et al Annals Allergy, Asthma and Immunology https://doi.org/10.1016/j.anai.2023.03.030 8

------

![LOGO](g874022g12a01.jpg)

Ozureprubart has a longer half-life, deeper and sustained pharmacodynamics with comparable efficacy vs approved anti-IgE, and less frequent dosing Phase I Half-life 60 days vs omalizumab 26 days Pharmacodynamics (free IgE) deeper and more sustained reduction vs omalizumab1 Pharmacokinetics2 Phase II in chronic spontaneous urticaria3 Comparable efficacy and safety to omalizumab Urticaria activity score 7 (UAS7) mean change from baseline4 1. Data derived from Shen et al, Clinical and Translational Science, 2025 Jun 12;18(6):e70264 2. https://www.sec.gov/Archives/edgar/data/1673772/000119312524283668/d926285dex993.htm 3. Not lead indication 4. https://investors.rapt.com/static-files/8391f631-637a-457d-a0d7-b3cc058e3ff3 Clinical development • Phase IIb (prestIgE) data assessing use of ozureprubart as monotherapy expected in 2027 • Phase III trials to be focused on both at-risk adult and paediatric populations 9

------

![LOGO](g874022g13a01.jpg)

Q&A GSK 10

## Ex-99.(A)(5)(B)

**Exhibit (a)(5)(b)**![LOGO](g874022g14u00.jpg)

Kaivan Khavandi 2nd Senior Vice President R&D, GSK 5h. Delighted to share the news of GSK'S agreement to acquire RAPT Therapeutics. Food allergies are highly prevalent and pose substantial burden and risk to adults and children with allergic reactions, including anaphylaxis, to a variety of potential allergens. This acquisition brings a potentially best-in-class anti-lgE antibody, in development to provide prophylactic protection for these patients. Having led organisations across target discovery, development, pre-launch and marketed products, I pay close attention not only to mechanistic translation of a target/therapeutic hypothesis through clinical POC, but also translation of trial datasets into real-world benefit. For the latter, I believe focusing on comorbidities ("phenotypes") and dosing characteristics are the most tractable variables to impact benefit. To this end, the deal will further bolster our growing portfolio of innovative long- and ultra-long acting biologics and oligonucleotides, benefiting from targeted and predictable pharmacology with favourable dosing characteristics. It is also another example of understanding and addressing the many permutations of imbalance and maladaptation that can be observed in the immune system, with therapeutics that can provide safe ways to restore this back to homeostatic health.

## Ex-99.(A)(5)(C)

**Exhibit (a)(5)(c)**![LOGO](g874022g15u00.jpg)

Chris Sheldon, Phd 1st Senior Vice President @ GSK \| Business Development 9h After a bus week at #JPM2026, what a brilliant start to the year for GSK as we announce today the acquisition of RAPT Therapeutics! RAPT Therapeutics is a California-based biotech with an exciting potential best-in-class Phase IIb medicine, a monoclonal antibody, for protection against allergic and inflammatory immune response. In the US alone, food allergies affect around 17 million people and cost S families up to $33 billion in economic cost. The remains an area of significant unmet need. This deal reflects our focused Business Development strategy of bolt-on M&A to further strengthen our pipeline, in this case complementing our existing expertise in immunology and long-acting technologies. Congrats to all involved in this transaction over the Christmas & New Year period & we looking forward to working with the talented team at RAPT Therapeutics to progress this medicine for patients. #Partnering